Kane Biotech Inc., a Winnipeg-based innovator in advanced wound care solutions, has taken a significant step in its U.S. commercialization strategy by securing a key distribution partnership. The company announced its collaboration with Marathon Medical Corporation, a Service-Disabled Veteran-Owned Small Business (SDVOSB) that specializes in healthcare distribution to federal agencies, including the U.S. Department of Veterans Affairs (VA), the Department of Defense (DOD), and Indian Health Services (IHS).
This partnership provides Kane Biotech with access to Marathon’s established procurement pathways within the U.S. government system. Marathon’s extensive experience in federal healthcare logistics and its national distribution network will streamline the onboarding and delivery of Kane’s revyve® Antimicrobial Wound Gel and other advanced wound care products. The collaboration aims to enhance accessibility to innovative wound care treatments for veterans, active service members, and indigenous communities.
Strategic Growth in the U.S.
As part of this expansion, Kane Biotech is also building a contract-based sales team across the United States. This geographically diverse network of sales representatives is expected to bolster Kane’s national presence and accelerate the availability of its advanced wound care solutions to clinicians and healthcare providers.
Dr. Robert Huizinga, Interim CEO of Kane Biotech, emphasized the significance of these initiatives. "We are continuing to strategically build the commercial infrastructure required to make revyve a national brand in advanced wound care", he said. "Our new contract-based sales agents expand our reach into key markets, while our partnership with Marathon Medical gives us a powerful foothold within the U.S. government system - an essential step in making revyve accessible to the veterans, active service members, and indigenous peoples."
sbb-itb-f5765c6
About the Partnership
Marathon Medical Corporation, headquartered in Aurora, Colorado, has been a leading medical supply distributor since 2002. As a federally verified SDVOSB, Marathon leverages its extensive government contract portfolio to deliver premium medical, surgical, and wound care products to federal healthcare agencies. The partnership with Kane Biotech aligns with Marathon’s mission to support federal healthcare systems with innovative and effective solutions.
Through this collaboration, Kane Biotech aims to overcome market entry barriers and establish itself as a pivotal player in the U.S. wound care market. The company’s revyve® Antimicrobial Wound Gel, which is both U.S. FDA 510(k) cleared and Health Canada approved, is designed to combat biofilms and improve wound healing outcomes. This product line also includes the revyve® Antimicrobial Wound Gel Spray and other related treatments.
Looking Ahead
Kane Biotech’s dual strategy of partnering with a seasoned distributor and investing in a national sales team marks a critical milestone in its efforts to scale operations in the U.S. market. By leveraging Marathon Medical’s expertise and its own cutting-edge wound care technologies, Kane Biotech is poised to make a meaningful impact in advanced wound care for underserved communities and federal healthcare systems.